The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

The first two cases of the new coronavirus (COVID-19) in Italy were recorded between the end of January and the beginning of February 2020. Since then, the number of cases in Italy increased steadily, reaching over 26.9 million as of January 8, 2025. The region mostly hit by the virus in the country was Lombardy, counting almost 4.4 million cases. On January 11, 2022, 220,532 new cases were registered, which represented the biggest daily increase in cases in Italy since the start of the pandemic. The virus originated in Wuhan, a Chinese city populated by millions and located in the province of Hubei. More statistics and facts about the virus in Italy are available here.For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

Status of COVID-19 cases in Ontario

This dataset compiles daily snapshots of publicly reported data on 2019 Novel Coronavirus (COVID-19) testing in Ontario.

Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak.

Effective April 13, 2023, this dataset will be discontinued. The public can continue to access the data within this dataset in the following locations updated weekly on the Ontario Data Catalogue:

• Ontario COVID-19 testing percent positive by age group
• Confirmed positive cases of COVID-19 in Ontario
• Ontario COVID-19 testing metrics by Public Health Unit (PHU)
• Ontario COVID-19 testing percent positive by age group
• COVID-19 cases in hospital and ICU, by Ontario Health (OH) region
• Cumulative deaths (new methodology)
• Deaths Involving COVID-19 by Fatality Type

For information on Long-Term Care Home COVID-19 Data, please visit: Long-Term Care Home COVID-19 Data.

Data includes:

• reporting date
• daily tests completed
• total tests completed
• test outcomes
• total case outcomes (resolutions and deaths)
• current tests under investigation
• current hospitalizations
  • current patients in Intensive Care Units (ICUs) due to COVID-related critical Illness
  • current patients in Intensive Care Units (ICUs) testing positive for COVID-19
  • current patients in Intensive Care Units (ICUs) no longer testing positive for COVID-19
  • current patients in Intensive Care Units (ICUs) on ventilators due to COVID-related critical illness
  • current patients in Intensive Care Units (ICUs) on ventilators testing positive for COVID-19
  • current patients in Intensive Care Units (ICUs) on ventilators no longer testing positive for COVID-19
• Long-Term Care (LTC) resident and worker COVID-19 case and death totals
• Variants of Concern case totals
• number of new deaths reported (occurred in the last month)
• number of historical deaths reported (occurred more than one month ago)
• change in number of cases from previous day by Public Health Unit (PHU).

This dataset is subject to change. Please review the daily epidemiologic summaries for information on variables, methodology, and technical considerations.

Cumulative Deaths

**Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool **

The methodology used to count COVID-19 deaths has changed to exclude deaths not caused by COVID. This impacts data captured in the columns “Deaths”, “Deaths_Data_Cleaning” and “newly_reported_deaths” starting with data for March 11, 2022. A new column has been added to the file “Deaths_New_Methodology” which represents the methodological change.

The method used to count COVID-19 deaths has changed, effective December 1, 2022. Prior to December 1, 2022, deaths were counted based on the date the death was updated in the public health unit’s system. Going forward, deaths are counted on the date they occurred.

On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. A small number of COVID deaths (less than 20) do not have recorded death date and will be excluded from this file.

CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags.

Related dataset(s)

• Confirmed positive cases of COVID-19 in Ontario

As of January 1, 2025, the number of active coronavirus (COVID-19) infections in Italy was approximately 218,000. Among these, 42 infected individuals were being treated in intensive care units. Another 1,332 individuals infected with the coronavirus were hospitalized with symptoms, while approximately 217,000 thousand were in isolation at home. The total number of coronavirus cases in Italy reached over 26.9 million (including active cases, individuals who recovered, and individuals who died) as of the same date. The region mostly hit by the spread of the virus was Lombardy, which counted almost 4.4 million cases.For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

As of November 11, 2022, almost 96.8 million confirmed cases of COVID-19 had been reported by the World Health Organization (WHO) for the United States. The pandemic has impacted all 50 states, with vast numbers of cases recorded in California, Texas, and Florida.

The coronavirus in the U.S. The coronavirus hit the United States in mid-March 2020, and cases started to soar at an alarming rate. The country has performed a high number of COVID-19 tests, which is a necessary step to manage the outbreak, but new coronavirus cases in the U.S. have spiked several times since the pandemic began, most notably at the end of 2022. However, restrictions in many states have been eased as new cases have declined.

The origin of the coronavirus In December 2019, officials in Wuhan, China, were the first to report cases of pneumonia with an unknown cause. A new human coronavirus – SARS-CoV-2 – has since been discovered, and COVID-19 is the infectious disease it causes. All available evidence to date suggests that COVID-19 is a zoonotic disease, which means it can spread from animals to humans. The WHO says transmission is likely to have happened through an animal that is handled by humans. Researchers do not support the theory that the virus was developed in a laboratory.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group.

Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak.

Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool

Data includes:

• Date on which the death occurred
• Age group
• 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated
• 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated
• 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster

Additional notes

As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm.

As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category.

On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023.

CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags.

The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON.

“Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results.

Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts.

Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different.

Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported.

Rates for the most recent days are subject to reporting lags

All data reflects totals from 8 p.m. the previous day.

This dataset is subject to change.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which, since 2019 in China, has rapidly become a worldwide pandemic. The aggressiveness and global spread were enhanced by the many SARS-CoV-2 variants that have been isolated up to now. These mutations affect mostly the viral glycoprotein Spike (S), the capsid protein mainly involved in the early stages of viral entry processes, through the recognition of specific receptors on the host cell surface. In particular, the subunit S1 of the Spike glycoprotein contains the Receptor Binding Domain (RBD) and it is responsible for the interaction with the angiotensin-converting enzyme 2 (ACE2). Although ACE2 is the primary Spike host receptor currently studied, it has been demonstrated that SARS-CoV-2 is also able to infect cells expressing low levels of ACE2, indicating that the virus may have alternative receptors on the host cells. The identification of the alternative receptors can better elucidate the pathogenicity and the tropism of SARS-CoV-2. Therefore, we investigated the Spike S1 interactomes, starting from host membrane proteins of non-pulmonary cell lines, such as human kidney (HK-2), normal colon (NCM460D), and colorectal adenocarcinoma (Caco-2). We employed an affinity purification-mass spectrometry (AP-MS) to pull down, from the membrane protein extracts of all cell lines, the protein partners of the recombinant form of the Spike S1 domain. The purified interactors were identified by a shotgun proteomics approach. The lists of S1 potential interacting proteins were then clusterized according to cellular localization, biological processes, and pathways, highlighting new possible S1 intracellular functions, crucial not only for the entrance mechanisms but also for viral replication and propagation processes.

This online data set accompanies the manuscript entitled "Free energy
simulations of receptor-binding domain opening in the SARS-CoV-2 spike
indicate a barrierless transition with slow conformational motions."

The dataset is composed of the following files:

* pmf0-now.dcd -- pmf63-now.dcd : molecular dynamics trajectory frames in
each of the 64 umbrella sampling windows, from which water has been
removed to save space

* s1am_0-now.pdb -- s1am_63-now.pdb : initial coordinates in each of the 64
umbrella sampling windows, from which water has been removed,
corresponding to the trajectory data above

* view -- Visual Molecular Dynamics command script to load a trajectory,
e.g., in Linux, use "vmd -e view"

* s1am_0-cg.dcd -- s1am_63-cg.dcd : molecular dynamics
trajectory frames in each of the 64 umbrella sampling windows, coarse-grained to
1 bead per residue.

* s1am_0-cg.pdb -- s1am_63-cg.pdb : initial coordinates in each of the 64
umbrella sampling windows, corresponding to the coarse-grained trajectory
data above.

* viewcg -- Visual Molecular Dynamics command script to load a
coarse-grained trajectory, e.g., in Linux, use "vmd -e viewcg"

* 0readme -- brief instructions on how to view the trajectories

* colors.vmd -- utility script for VMD

* covmacros.vmd -- VMD script to define coronavirus spike subdomains

* fe.zip -- ZIP archive that contains data and Matlab analysis files to
reproduce the free energy profiles

* diff.zip -- ZIP archive that contains data and Matlab analysis files to
reproduce the diffusion and mean first passage times calculations

* pca-qha.zip -- ZIP archive that contains the data and Matlab analysis files
to compute the autocorrelation functions of trajectory displacements
along principal/quasiharmonic modes

Each ZIP archive contains a "0readme" file with brief instructions, and also the
results of the calculations

As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.

The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.

Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.

A recent pandemic caused by a single-stranded RNA virus, COVID-19, initially discovered in China, is now spreading globally. This poses a serious threat that needs to be addressed immediately. Genome analysis of SARS-CoV-2 has revealed its close relation to SARS-coronavirus along with few changes in its spike protein. The spike protein aids in receptor binding and viral entry within the host and therefore represents a potential target for vaccine and therapeutic development. In the current study, the spike protein of SARS-CoV-2 was explored for potential immunogenic epitopes to design multi-epitope vaccine constructs. The S1 and S2 domains of spike proteins were analyzed, and two vaccine constructs were prioritized with T-cell and B-cell epitopes. We adapted a comprehensive predictive framework to provide novel insights into immunogenic epitopes of spike proteins, which can further be evaluated as potential vaccine candidates against COVID-19. Prioritized epitopes were then modeled using linkers and adjuvants, and respective 3D models were constructed to evaluate their physiochemical properties and their possible interactions with ACE2, HLA Superfamily alleles, TLR2, and TLR4.

Coronavirus disease-2019 (COVID-19) is a lethal respiratory illness caused by the coronavirus SARS-CoV-2. A thorough understanding of the molecular mechanisms of cellular infection by coronaviruses is therefore of utmost importance. A critical stage in infection is the fusion between viral and host membranes, which is mediated by the viral Spike Protein. It has now become clear that membrane fusion during viral entry is a cooperative process likely involving the contribution of different sections of the fusion domain, which may also be dependent on the nature and the composition of the lipid mixtures. To address this, we will employ NR to investigate the membrane binding activity of the Fusion domain and Core of the Spike S2 domain, upon interaction with natural lipid bilayers and compare these results with our previous findings involving minimal models with single peptides.

The COVID-19 pandemic, caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe global health crisis now. SARS-CoV-2 utilizes its Spike protein receptor-binding domain (S-protein) to invade human cell through binding to Angiotensin-Converting Enzyme 2 receptor (ACE2). S-protein is the key target for many therapeutics and vaccines. Potential S-protein–ACE2 fusion inhibitor is expected to block the virus entry into the host cell. In many countries, traditional practices, based on natural products (NPs) have been in use to slow down COVID-19 infection. In this study, a protocol was applied that combines mixed solvent molecular dynamics simulations (MixMD) with high-throughput virtual screening (HTVS) to search NPs to block SARS-CoV-2 entry into the human cell. MixMD simulations were employed to discover the most promising stable binding conformations of drug-like probes in the S-protein–ACE2 interface. Detected stable sites were used for HTVs of 612093 NPs to identify molecules that could interfere with the S-protein–ACE2 interaction. In total, 19 NPs were selected with rescoring model. These top-ranked NP–S-protein complexes were subjected to classical MD simulations for 300 ns (3 replicates of 100 ns) to estimate the stability and affinity of binding. Three compounds, ZINC000002128789, ZINC000002159944 and SN00059335, showed better stability in all MD runs, of which ZINC000002128789 was predicted to have the highest binding affinity, suggesting that it could be effective modulator in RBD-ACE2 interface to prevent SARS-CoV-2 infection. Our results support that NPs may provide tools to fight COVID-19.

The results of a survey showed a spike in the involvement of household chores as a result of the coronavirus (COVID-19) lockdown across India in April 2020. Other popular activities included watching movies and TV shows online, exercising at home and making video calls to family/friends.

A lockdown was enforced on March 25, 2020 for 21 days, the largest in the world, restricting 1.3 billion people, now extended until May 3, 2020. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Fact and Figures page.